Article

SURGE: Sound Understanding of Real Glaucoma Efficacy

Panelists at a CME symposium on Saturday evening provided an in-depth review of current information on the results of early detection and treatment with lipid therapy. Prostaglandin and prostamide drugs are widely used to lower IOP, and speakers discussed clinical data on these drugs as well as the differences between the three once-daily lipids available today.

Chicago-Panelists at a CME symposium on Saturday evening provided an in-depth review of current information on the results of early detection and treatment with lipid therapy. Prostaglandin and prostamide drugs are widely used to lower IOP, and speakers discussed clinical data on these drugs as well as the differences between the three once-daily lipids available today.

As part of their discussion of lipids, speakers also explored topics such as systemic optic nerve evaluation, guidelines for glaucoma management, and challenges in clinical practice, such as patient compliance, adherence, and communication.

Presenters included Louis B. Cantor, MD, Indiana University School of Medicine; Ronald L. Gross, MD, Cullen Eye Institute, Baylor College of Medicine, Houston; Leon W. Herndon, MD, Duke University Eye Center, Durham, NC; Robert J. Noecker, MD, MBA, University of Pittsburgh; and Steven T. Simmons, MD, Albany Medical College, Albany, NY.

Dr. Cantor discussed methods of evaluating endpoints and treatment goals and noted that clinical trials sponsored by the National Eye Institute have answered key questions about the benefits of lowering IOP in different patients. Conclusions that can be drawn include:

  • Early treatment reduces and delays glaucoma progression.
  • Regardless of stage, lowest IOP is the critical factor in preventing disease progression.
  • Every mm Hg counts.
  • It is vital to maintain a steady level of IOP over time.

“If you want to place your patients in the best possible condition, lower is better,” Dr. Cantor emphasized.

If medical therapy is analogous to building a house and primary therapy is the foundation, physicians need to be aware that many patients experience moderate-to-large diurnal fluctuations in their IOP while on primary therapy, typically a prostaglandin.

“Your foundation is on sand if your foundation is fluctuating,” suggested Dr. Simmons, explaining that it is difficult to tell if therapy is working if IOP varies up to 8 to 10 mm Hg from measurement to measurement.

He advised physicians try to determine which medication causes the least fluctuation in individual patients. He also recommended that they consider switching medication before adding a second, since compliance drops as more medications are added. Also, evidence suggests that the often-used combination of a prostaglandin and a beta-blocker is ineffective in many patients.

The program was jointly sponsored by Ophthalmology Times and the New York Eye and Ear Infirmary and supported by an unrestricted educational grant from Allergan. The event was held at the Cadillac Club at Soldier Field.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.